| Literature DB >> 33791262 |
Alireza Basharkhah1, Herwig Lackner2, Anna Karastaneva2, Marko Bergovec3, Stephan Spendel4, Christoph Castellani1, Erich Sorantin5, Martin Benesch2, Bernadette Liegl-Atzwanger6, Freyja-Maria Smolle-Jüttner7, Christian Urban2, Michael Höllwarth1, Georg Singer1, Holger Till1.
Abstract
Introduction: Ewing sarcomas of the chest wall, historically known as "Askin tumors" represent highly aggressive pediatric malignancies with a reported 5-year survival ranging only between 40 and 60% in most studies. Multimodal oncological treatment according to specific Ewing sarcoma protocols and radical "en-bloc" resection with simultaneous chest wall repair are key factors for long-term survival. However, the surgical complexity depends on tumor location and volume and potential infiltrations into lung, pericardium, diaphragm, esophagus, spine and major vessels. Thus, the question arises, which surgical specialties should join their comprehensive skills when approaching a child with Ewing sarcoma of the chest wall. Patients andEntities:
Keywords: Askin tumor; Ewing sarcoma; chemotherapy; chest wall reconstruction; multimodal therapy; tumor resection
Year: 2021 PMID: 33791262 PMCID: PMC8005523 DOI: 10.3389/fped.2021.661025
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.418
Figure 1Preoperative CT revealing multiple metastases: (A) shows a paraesophageal metastasis (red circle) and (B) demonstrates a pericardial metastasis (red circle). Both were removed surgically during initial resection (Patient #13).
Clinical data of 13 patients treated with Askin tumors between 1990 and 2020.
| 1 | 1990 | 7 | M | 6th−7th | Right | Adherent to lung |
| 2 | 1994 | 21 | M | 8th | Right | Pleura, adherent to diaphragm |
| 3 | 2001 | 16.5 | M | 6th | Right | Malignant pleural effusion |
| 4 | 2001 | 2.5 | F | 11th | Right | Adherent to diaphragm |
| 5 | 2001 | 10.5 | M | 4th | Right | Adherent to lung |
| 6 | 2001 | 18 | F | 9th | Left | adherent to diaphragm |
| 7 | 2009 | 12 | F | 4th−6th | Right | Left lower lobe, malignant pleural effusion |
| 8 | 2012 | 16.5 | M | 7th | Left | Malignant pleural effusion, tumor embolism, adherent to diaphragm and the lung lower lobe |
| 9 | 2014 | 11 | M | 4th | Left | Malignant pleural effusion, adherent to the lung lower and upper lobe |
| 10 | 2017 | 3 | F | 7th | Left | Adherent to vertebral body and transverse process |
| 11 | 2018 | 8 | M | 3th | Right | Adherent to lung |
| 12 | 2019 | 9 | F | 6th | Right | Pleura |
| 13 | 2020 | 11.5 | F | 3th | Left | Pleura, left lower lobe, diaphragmatic, paraesophageal, pericardial |
Treatment of 13 patients with Askin tumors.
| 1 | CESS 86/irradiation | 32 | 4 | Resection of the dorsal part of the 6th, the entire 7th rib, the transverse process and partial resection of the lung lower lobe | PS | ||
| 2 | EICESS 92/irradiation | 810 | 215 | Partial resection of the 7th−9th ribs with adherent diaphragm | TS | Corium flap plastic and m. latissimus dorsi flap at a later time point autologous transplantation of the contralateral 7th rib and m. rectus abdominis flap at a later time point | |
| 3 | EURO EWING 99 | 148 | 2 | Partial resection of the 5th−7th ribs | PS, OT | Vicryl® mesh and m. latissimus dorsi flap | |
| 4 | EURO EWING 99 | 246.5 | 16 | Partial resection of the 10th−12th ribs with adherent diaphragm | PS, PL | Vicryl® mesh and m. latissimus dorsi flap | |
| 5 | EURO EWING 99 | 813.7 | 15.2 | Partial resection of the 3rd−5th ribs with adherent lung | PS | Goretex® patch, Vicryl® mesh | |
| 6 | EURO EWING 99 | 199 | 5.2 | Partial resection of the 8th−10th ribs with adherent diaphragm | PS | Goretex® patch, Vicryl® mesh | |
| 7 | CWS 2002 pilot | 216 | 88.6 | Partial resection of the 4th−7th ribs | PS | Tutomesh® plastic and m. latissimus dorsi flap | |
| 8 | EWING 2008 | 175 | 8.8 | Partial resection of the 5th−9th ribs with adherent diaphragm and the lung lower lobe | OT, TS | Gore® Dualmesh®, Prolene® Mesh m. latissimus dorsi flap | |
| 9 | EWING 2008 | 310 | 37 | Partial resection of the 3rd−7th ribs and the adherent lung lower and upper lobe | PS, TS, PL | Prolene® Mesh m. latissimus dorsi flap | |
| 10 | EWING 2008 | 72 | 15 | Partial resection of 6th−8th with partial vertebral body resection/hemilaminectomy, resection of the transverse process and dorsal root ganglia | PS, OT, PL | Prolene® Mesh m. latissimus dorsi flap and m. trapezius | Liquor fistula lumbar drainage |
| 11 | EWING 2008 | 83 | 5.4 | Partial resection of 2nd−4th ribs and adherent lung | PS, OT, PL | Prolene® Mesh m. pectoralis flap | |
| 12 | EWING 2008/ irradiation | 53.1 | 2 | Partial resection of the 4th−6th and pleural metastases | PS, OT, PL | Prolene® Mesh m. latissimus dorsi flap | |
| 13 | EWING 2008 | 814 | 158 | Partial resection of the 1st−5th ribs with metastases to pericardium, lung, diaphragm | PS, OT, PL | Prolene® Mesh m. latissimus dorsi flap |
CTX, chemotherapy; PS, Pediatric Surgery; OT, Orthopedic Surgery; PL, Plastic Surgery; TS, Thoracic Surgery; CDC, Clavien-Dindo Classification.
Figure 2Tumor arising from the paravertebral dorsal portion of the left 7th rib with infiltration of the transverse process and vertebral body. This extent required en bloc resection of the ribs 6–8 and additional removal of the costovertebral joint and hemilaminectomy (patient #10).
Outcome and complications of 13 patients treated with Askin tumors.
| 1 | R0 | 1 | +/– | – | 30.7 | Scoliosis, pulmonary restriction | |
| 2 | R0 | 1 | +/– | + | Lung/local | ||
| 3 | R0 | 1 | +/+ | – | – | 20 | |
| 4 | R0 | 1 | +/– | – | – | 19.9 | |
| 5 | R0 | 3 | +/– | – | – | 19.5 | |
| 6 | R0 | 1 | +/– | – | – | 19.4 | |
| 7 | R0 | 5 | +/+ | + | Lung bilateral | †1.5 | |
| 8 | R0 | 1 | +/refused | + | – | 8.8 | |
| 9 | R0 | 1 | +/– | + | – | 7 | Pulmonary restriction |
| 10 | R1 | 5 | +/+ | – | Local/cervical | 3.4 | Scoliosis |
| 11 | R0 | 1 | +/– | – | – | 2.9 | |
| 12 | R0 | 1 | +/– | + | – | 1.2 | |
| 13 | Marginal | 5 | +/+ | + | – | 0.9 |
CTX, chemotherapy; PSCTx, peripheral stem cell transplantation.
deceased.